Stifel lowered the firm’s price target on Alcon (ALC) to $70 from $82 and keeps a Hold rating on the shares. The firm’s previous downgrade of shares in January questioned the company’s ability to post 2026 top-line upside and “only one quarter in, this part of our thesis may already be playing out,” the analyst tells investors. The downgrade expressed equal caution around a likely 2027 top-line deceleration and this deceleration “arguably may be of greater concern,” the analyst added.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALC:
- Alcon Q1 2026 Sales Rise 10% as New Eye-Care Products Power Growth and $1.5 Billion Buyback
- Analyst Reiterates Sell on Execution and Valuation Risks, Trims Price Target to CHF 55 Amid Competitive Pressures
- Alcon price target lowered to $87 from $92 at BTIG
- William Blair med tech analyst holds an analyst/industry conference call
- Alcon launches Clareon TruPlus at ASCRS 2026
